Inventor · disambiguated record
Yuli Xie
Also filed as: XIE YULI
19 granted patents·20 pending applications·17 citations·filing 2007–2024
90Inventor score
Files withWIGEN BIOMEDICINE TECH SHANGHAI CO LTD22UNIV COLUMBIA8KARSENTY GERARD2AMBRON RICHARD1GOUAUX ERIC1
Top patents by PatentIndex Score
39 records- 0184US9402826B2Neuronal pain pathway modulatorsUNIV COLUMBIA·Filed 2014·Granted Aug 2, 2016·3 cites·2 claims
- 0284US8846742B2Neuronal pain pathway modulatorsAMBRON RICHARD·Filed 2007·Granted Sep 30, 2014·4 cites·1 claims
- 0378US11021457B2Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereofWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2018·Granted Jun 1, 2021·2 cites·9 claims
- 0476US9012471B2Glucose metabolism modulating compoundsHARRIS PAUL·Filed 2009·Granted Apr 21, 2015·2 cites·12 claims
- 0572US8759364B2Methods of treating bone mass diseasesKARSENTY GERARD·Filed 2009·Granted Jun 24, 2014·2 cites·2 claims
- 0671US12122774B2Compounds as MYT1 inhibitorsWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2024·Granted Oct 22, 2024·0 cites·16 claims
- 0771US11319303B2Compound used as autophagy regulator, and preparation method therefor and uses thereofWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2018·Granted May 3, 2022·1 cites·6 claims
- 0867US8653273B2Potent non-urea inhibitors of soluble epoxide hydrolaseRINDERSPACHER KIRSTEN ALISON·Filed 2011·Granted Feb 18, 2014·2 cites·14 claims
- 0963US8685963B2Compounds that inhibit NFκB and BACE1 activityLANDRY DONALD W·Filed 2011·Granted Apr 1, 2014·1 cites·4 claims
- 1058US9175285B2Potent non-urea inhibitors of soluble epdxide hydrolaseUNIV COLUMBIA·Filed 2014·Granted Nov 3, 2015·0 cites·10 claims
- 1158US2025154134A1Compound as fak inhibitor and use thereofWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2023·Application pending·0 cites
- 1258US2024317741A1Naphthyridine derivative as atr inhibitor and method for preparing sameWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1357US2018305314A1Potent non-urea inhibitors of soluble epoxide hydrolaseUNIV COLUMBIA·Filed 2018·Application pending·0 cites
- 1454US2024208978A1Idh mutant inhibitor and use thereofWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1554US2024182482A1Fused cyclic compound as wee-1 inhibitor, preparation method therefor and use thereofWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1653US12351582B2Aurora kinase inhibitors and uses thereofWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2021·Granted Jul 8, 2025·0 cites·6 claims
- 1753US11993598B2Compounds for inhibiting EGFR kinase, preparation methods and uses thereofWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2021·Granted May 28, 2024·0 cites·3 claims
- 1853US10005732B2Potent non-urea inhibitors of soluble epoxide hydrolaseUNIV COLUMBIA·Filed 2015·Granted Jun 26, 2018·0 cites·12 claims
- 1953US2024336624A1Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereofWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 2053US2025197382A1Kif18a inhibitorWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2023·Application pending·0 cites
- 2153US2023416270A1Novel camptothecin derivative, composition comprising same and use thereofWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 2252US12391692B2Spiro ring-containing quinazoline compoundWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2021·Granted Aug 19, 2025·0 cites·7 claims
- 2351US12479843B2Spiro ring-containing quinazoline compoundsWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2020·Granted Nov 25, 2025·0 cites·18 claims
- 2451US12275726B2Aurora kinase inhibitors and use thereofWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2020·Granted Apr 15, 2025·0 cites·7 claims
- 2551US2025042904A1Compounds used as src inhibitorsWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 2650US12497397B2Pyrrole compounds useful as antifungalsWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2020·Granted Dec 16, 2025·0 cites·10 claims
- 2750US2009270508A1GluR2 receptor modulatorsGOUAUX JAMES ERIC·Filed 2009·Application pending·0 cites
- 2849US11286247B2Acryloyl-containing nuclear transport regulators and uses thereofWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2020·Granted Mar 29, 2022·0 cites·11 claims
- 2949US2024158369A1Pyrimidine compound as wee-1 inhibitorWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 3049US2014275165A1COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITYUNIV COLUMBIA·Filed 2014·Application pending·0 cites
- 3149US2023130909A1Hpk1 inhibitor, preparation method therefor and use thereofWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 3249US2024182447A1Fused ring compound as wee-1 inhibitorWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 3348US9260391B2Hypoglycemic dihydropyridonesXIE YULI·Filed 2009·Granted Feb 16, 2016·0 cites·65 claims
- 3447US2015111908A1Methods of diagnosing, preventing, and treating bone mass diseasesKARSENTY GERARD·Filed 2014·Application pending·0 cites
- 3546US2010204258A1Methods and compositions for modulating insulin secretion and glucose metabolismUNIV COLUMBIA·Filed 2008·Application pending·0 cites
- 3645US2016311773A1Glucose metabolism modulating compoundsUNIV COLUMBIA·Filed 2015·Application pending·0 cites
- 3740US2007293573A1Glu2 receptor modulatorsGOUAUX ERIC·Filed 2007·Application pending·0 cites
- 3840US2020069609A1Method for covalent bond modifying mammalian atg8 homologueWIGEN BIOMEDICINE TECH SHANGHAI CO LTD·Filed 2018·Application pending·0 cites
- 3939US2011071124A1Compounds that Inhibit Production of sAPPB and AB and Uses ThereofUNIV COLUMBIA·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yuli Xie files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →